YousifAbdelmoneimMDM.B.B.S., M.D.

Internal Medicine • Atlantic Beach, FL

Hematology/Oncology

M.B.B.S., M.D.

Join to view full profile

Dr. Abdelmoneim is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Abdelmoneim's full profile

Already have an account?

Office
4500 San Pablo Rd S
Atlantic Beach, FL 32224

Summary

Dr. Yousif Abdelmoneim is affiliated with Mayo Clinic Hospital in Florida. He received his medical degree from University of Gezira Faculty of Medicine and has been in practice 5 years. He also speaks multiple languages, including Arabic. He is experienced in lung transplantation, lung malignancies, genitourinary malignancies, and melanoma. He has 8 publications and 4 citing.

Clinical Expertise

Advanced cardiac life support, Lung transplantation, Non-small cell lung carcinoma, Small-cell lung carcinoma, Lung cancer, Genitourinary cancer, HLA testing, Nephrology, Oncology, Kidney transplantation, Pediatric advanced life support, Clinical research, Transplant immunology, Leadership, Laboratory research, Internal medicine, Point-of-care ultrasonography, Immunology, Clincial trials, HLA tissue typing, Direct Patient Care

Education & Training

University Of GeziraMD, Internal medicine , 2015 - 2018
University of Gezira Faculty of Medicine MBBS, Medicine, Surgery, MBBS, 2008 - 2014
University of Gezira Faculty of MedicineClass of 2014

Awards, Honors, & Recognition

Reviewer Certificate Wiley/ Immunity, inflammation and disease, 2023
Medical student of the year University of Gezira Faculty of Medicine, 2013-2014
Full Medical School Scholarship University of Gezira Faculty of Medicine, 2008-2014
Chess Tournament Winner University of Gezira, 2012
Top ten high school student African Council for Private Education, 2006-2008
Artist of the year African Council for Private Education, 2006-2008
Full High School Scholarship African Council for Private Education, 2005-2008
Join now to see all

Clinical Trials

International Registry for Men With Advanced Prostate Cancer (IRONMAN) Start of enrollment: 2017 Jul 21
Recruiting
MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Start of enrollment: 2015 Jan 03
Active, not recruiting
Phase 3
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma Start of enrollment: 2022 Sep 30
Recruiting
Phase 1
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study Start of enrollment: 2022 Jun 14
Active, not recruiting
Phase 1
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments Start of enrollment: 2019 Oct 01
Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin Start of enrollment: 2020 Oct 27
Recruiting
Phase 3
Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer Start of enrollment: 2021 Jul 01
Completed
Early Phase 1
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations Start of enrollment: 2020 Mar 11
Terminated
Phase 3
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Start of enrollment: 2019 Nov 18
Active, not recruiting
Phase 1, Phase 2
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer Start of enrollment: 2018 Oct 10
Active, not recruiting
Phase 2
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer Start of enrollment: 2017 Oct 11
Active, not recruiting
Phase 1, Phase 2
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Start of enrollment: 2018 Dec 24
Recruiting
Phase 3
CemiplimAb Survivorship Epidemiology Start of enrollment: 2019 Jun 27
Active, not recruiting
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer Start of enrollment: 2019 Apr 05
Active, not recruiting
Phase 3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy Start of enrollment: 2019 Jun 11
Active, not recruiting
Phase 3
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) Start of enrollment: 2018 Sep 12
Active, not recruiting
Phase 3
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) Start of enrollment: 2018 Oct 01
Active, not recruiting
Phase 2
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Start of enrollment: 2018 Apr 24
Active, not recruiting
Phase 3
A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma Start of enrollment: 2018 Apr 11
Active, not recruiting
Phase 2, Phase 3
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 1, Phase 2
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma Start of enrollment: 2018 Oct 05
Recruiting
Phase 2
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Start of enrollment: 2014 May 14
Completed
Phase 1, Phase 2
Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) Start of enrollment: 2022 Mar 24
Active, not recruiting
Phase 3
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients Start of enrollment: 2022 Aug 01
Recruiting
Phase 1, Phase 2
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Start of enrollment: 2022 Nov 28
Recruiting
Phase 2
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC Start of enrollment: 2022 Oct 10
Recruiting
Phase 1
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations Start of enrollment: 2022 Dec 29
Recruiting
Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC Start of enrollment: 2022 Feb 18
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Basiliximab is associated with a lower incidence of De novo donor-specific HLA antibodies in kidney transplant recipients: A single-center experience.
Tambi Jarmi, Yousif Abdelmoneim, Zhuo Li, Abdullah Jebrini, Mohamed Elrefaei
Transplant Immunology. 2023-04-01
3 citations
Association between SARS-CoV-2 infection and de novo HLA donor specific antibody production in lung transplant recipients: Single-center study.
Sadia Z Shah, Yousif Abdelmoneim, Si M Pham, Mohamed Elrefaei
Human Immunology. 2022-11-01
1 citations
Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibody detection in lung transplant recipients: A single-center experience.
Tathagat Narula, Samir Khouzam, Francisco Ginés Laredo Álvarez, David B. Erasmus, Zhuo Li
Immunity, Inflammation and Disease. 2021-07-26

Journal Articles

Assessment of Knowledge Regarding Risks and Benefits of the Use of Non Vitamin K Antagonist Oral Anticoagulants
Jose Raul Valery1 , Ahmad Marar2, George Pujalte3, Cynthia Ward4, Yousif M. Abdelmoneim5, Patrick J. Fitzgerald1, Edson Mwakyanjala1, Dana M. Harris1 , Loren Murray1..., Primary care and community health, 8/24/2022
Association between SARS-CoV-2 infection and de novo HLA donor specific antibody production in lung transplant recipients: Single-center study
Sadia Z. Shah a , Yousif Abdelmoneim b , Si M. Pham c , Mohamed Elrefaei b, Human Immunology, 8/15/2022
Antithymocyte globulin is associated with a lower incidence of de novo donor-specific antibody detection in lung transplant recipients: A single-center experience
Tathagat Narula, Samir Khouzam, Francisco Alvarez, David Erasmus, Zhuo Li, Yousif Abdelmoneim, Mohamed Elrefaei, Immunity, Inflammation and Disease, 7/26/2021
A Comparison of Transradial vs. Transfemoral Cerebral Angiography.
Mohammad R. Ghani, Suganya Marudhai, Mauli Patel, Noha Eskander, Yousif M. Abdelmoneim, Ahmad Jan., Cureus, 10/12/2020
Join now to see all